The purpose of the study is to find out if mosliciguat, the investigational drug that is being studied, with treprostinil, is safe and effective in treating adults who live with PH-ILD. Approximately 20 participants diagnosed with PH-ILD who are currently on a stable dose of inhaled treprostinil who meet all inclusion and no exclusion criteria will be enrolled. Part 1 of the study will take about 5 ½ months. Part 2 of the study is optional if you choose to participate in the extension period. Part 2 does not have a set end date and your participation in Part 2 will end if you or your study doctor decide to stop your participation or the Sponsor ends the study.

Quantitative survey of certain substances of abuse in the adolescent and young adult population of SC. Survey study will be focused on substances of abuse that are easily accessible at a gas station due to little to no regulations or excessive amounts available in various forms such as Kratom, 7-OH, Tia, nicotine pouches, THC, etc.

This is a Phase 3, open-label, follow-up study to evaluate the long-term safety,
tolerability, and efficacy of sotatercept when added to background PAH therapy for the treatment of PAH. Participants enrolled in this study are from the following parent studies: PULSAR, SPECTRA, STELLAR, HYPERION, and ZENITH. Participants eligible to enroll in this study will have participated in and completed the requirements of the MK-7962-004 study (Amendment 07 or later). In this study, participants will receive open-label sotatercept . The duration of participation for each participant will vary based on their enrollment date, but it is anticipated to be up to 3 years.

This observational, multi-country cohort study examines the long-term safety of Filsuvez in real-world clinical practice. Researchers will collect both primary data and use existing patient registry data to gather information on Filsuvez exposure, skin malignancies, medical history, and other clinical characteristics. The study will include patients with confirmed diagnoses of DEB and JEB, regardless of whether they use Filsuvez, as long as they meet the approved indication. Patients previously exposed to Filsuvez through clinical trials, early access programs, or compassionate use programs may also participate. The study does not require any protocol-mandated visits or procedures, and the frequency of patient visits will follow local standard practice and individual patient needs.

This study is for patients that have been diagnosed with diagnosed with unresectable, locally advanced, recurrent or metastatic renal cell carcinoma (RCC). The study is testing investigational drugs called pumitamig."Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The main purpose of this study is to evaluate the safety and tolerability, and to determine the recommended phase 2 dose (RP2D), of pumitamig administered in combination with ipilimumab or cabozantinib. The study drug is given by infusion. Participants in this study can expect to be in this study for about 4 years.

This study is designed to improve how body image distress is identified among adult survivors of head and neck cancer during routine clinic visits. Participants will complete questionnaires about body image concerns either on paper or electronically (in clinic or remotely through a secure link). The study will evaluate how well a brief screening questionnaire (IMAGE-HN SF) identifies patients experiencing meaningful body image distress compared with the longer, full IMAGE-HN survey. In addition to assessing how accurately the short form performs, we will ask patients how they prefer the screening to be delivered, including the timing, format, and method of completion in routine care. A subset of participants will be invited to complete a short interview to share additional thoughts about how this type of screening should be implemented. Findings from this study will help guide the use of efficient and patient-centered body image screening in head and neck cancer clinics.

This an observational study collecting data for up to 8 years on patients who have been diagnosed with PiZZ or PiSZ Alpha-1 Antitrypsin Deficiency with or without liver disease. Patients' clinical, medical, and laboratory data will be collected prospectively per routine care and questionnaires will be collected during the clinic visits with the hopes of getting a better understanding of the natural progress of lung and liver disease associated with Alpha-1 Antitrypsin Deficiency.

This is a descriptive study designed to determine the proportion of women who are sexually active after minimally invasive sacrocolpopexy, with particular focus on those aged 65 and older. Because sacrocolpopexy carries certain risks—especially in older women—but also preserves vaginal length and may improve sexual function, understanding post-surgical sexual activity can help clinicians counsel patients when choosing between reconstructive surgeries, which preserve vaginal length, and obliterative surgeries, which do not. The study also aims to better understand patient values in surgical decision-making related to sexual activity. Women who had sacrocolpopexy at MUSC since January 1, 2015 will be contacted to complete two questionnaires: one assessing sexual activity and satisfaction with surgery, and one assessing sexual function using an adapted PISQ-IR questionnaire. Data will be analyzed using descriptive and comparative statistics to examine the proportion of sexually active women in groups under 65 versus 65 and older, as well as to compare their sexual function outcomes.

This study aims to improve cancer survivorship care work by refining how primary care providers and cancer specialists share responsibilities. Researchers want to understand how technology can help these teams communicate more clearly and effectively to coordinate care for survivors. The study team will use surveys, conduct interviews and organize focus groups for interested and eligible participants as methods of data collection to inform the research. Oncologists, Primary Care Physicians, administrative leads and colon or rectal cancer survivors that meet the eligibility criteria will complete surveys, engage in interviews and group discussions from each perspective to learn strategies to improve care, including who should handle which parts of survivorship care. Using this information, the team will create an intervention plan called PRIMES that outlines strategies to overcome common barriers. The ultimate goal is to help survivors receive better and more coordinated follow‑up care.

This study will evaluate whether using cold therapy before Anterior Cruciate Ligament (ACL) reconstruction surgery improves recovery during the first six weeks after surgery. Patients undergoing ACL reconstruction will either receive standard preoperative care or standard care plus a period of cold therapy prior to surgery. Pain levels, swelling, medication use, and functional recovery will be tracked using surveys and routine clinical follow-up information. participation will not change the surgical procedure or postoperative rehabilitation plan.